Mouse anti Human CD25, conjugated with FITCCatalog number: 0252
Identification of human receptor for Interleukin-2 (IL-2R) expressing the 55,000 M.W. surface antigen.
Immunogen: CD25=Derived from the hybridization of mouse NS-1 myeloma cells with spleen cells of BALB/c mice immunized with PHA-activated human T-lymphocytes.
Product Form: FITC
Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide and 0.2% carrier protein
Purification Method: Protein A/G Chromatography
Concentration: Titered for flow cytometry
PBMC: Add10 µl of MAB/10^6 PBMC in 100 µl PBS. Mix gently and incubate for 15 minutes at 2º to 8ºC. Wash twice with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. WHOLE BLOOD: Add10 µl of MAB/100 µl of whole blood. Mix gently and incubate for 15 minutes at room temperature 20ºC. Lyse the whole blood. Wash once with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. See instrument manufacturer’s instructions for Lysed Whole Blood and Immunofluorescence analysis with a flow cytometer or microscope.
Functional Analysis: Flow Cytometry Staining
Product should be stored at 4-8ºC. DO NOT FREEZE
Product Stability: See expiration date on vial
Shipping Conditions: Room Temperature
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Exalpha Biologicals accepts no liability for any inaccuracies or omissions in this information.
1. A Monoclonal Antibody (Anti-Tac) Reactive with Activated and Functionally Mature Human T Cells. Uchiyama T., Broder S., Waldmann TA, 1981 J. Immunol.126,1393. 2. Direct Demonstration of the Identity of T Cell Growth Factor Binding Protein and the Tac Antigen. Robb RJ, Greene WC, J. Exp. Med. 1983,158;1332. 3. Patients with HIV infection have a reduced proportion of lymphocytes expressing the IL2 receptor p55 chain (TAC, CD25). Zola H., Koh L.Y., Mantzioris B.X., Rhodes D., Clin. Immunol. Immunopathol. 1991 Ap:59(1):16-25. 4. Spontaneous lymphocyte proliferation in HTLV-I/II infection reflects preferential activation of CD8 and CD16/56 cell subsets. Prince H.E., Weber D.M., Jensen E.R., Clin. Immunol. Immunopathol. 1991, May;58(3):419-30. 5. Defective clonogenic potential of CD8+ T lymphocytes in patients with AIDS. Expansion in vivo of a nonclonogenic CD3+ CD8+ DR+ CD25- T cell population. Pantaleo G., Keonig S., Baseler M., Lane H.C., Fauci A.S., J. Immunol. 1990 Mar ; 144(5):1696-704.
Database Name: UniProt
Accession Number: P01589
Safety Datasheet(s) for this product: